Definium Therapeutics (DFTX) Other Non-Current Assets (2022 - 2026)
Definium Therapeutics (DFTX) posted quarterly Other Non-Current Assets of $812000.0 for Q1 2026, up 33.99% year-over-year from $606000.0 in Q1 2025, and down 5.8% quarter-over-quarter from $862000.0 in Q4 2025.
Powered by 
Analysis
Definium Therapeutics (DFTX) Other Non-Current Assets (2022 - 2026) Analysis & Trends
Definium Therapeutics (DFTX) has reported Other Non-Current Assets for 5 consecutive years, with $812000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 33.99% year-over-year to $812000.0; the TTM figure through Mar 2026 stood at $812000.0 (up 33.99% YoY), while the FY2025 annual figure was $862000.0, up 40.62% from the prior year.
- Other Non-Current Assets declined to $812000.0 in Q1 2026 per DFTX's latest filing, from $862000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $1.2 million in Q2 2025 and bottomed at $144000.0 in Q1 2024.
- Historically, Other Non-Current Assets has averaged $552857.1 across 5 years, with a median of $513500.0 in 2024.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets sank 52.0% — and 2025, when it surged 320.83%.
- Definium Therapeutics' Other Non-Current Assets stood at $331000.0 in 2022, then sank by 32.33% to $224000.0 in 2023, then surged by 173.66% to $613000.0 in 2024, then jumped by 40.62% to $862000.0 in 2025, then fell by 5.8% to $812000.0 in 2026.
- Business Quant data shows DFTX's Other Non-Current Assets at $812000.0 in Q1 2026, $862000.0 in Q4 2025, and $1.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 618.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 42.45 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 109.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 62.96 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Definium Therapeutics | 4.23 Bn | 4.23 Bn | - | 880,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 880,000.00 |
| Mar 31, 2026 | 812,000.00 |
| Dec 31, 2025 | 862,000.00 |
| Sep 30, 2025 | 1.15 Mn |
| Jun 30, 2025 | 1.17 Mn |
| Mar 31, 2025 | 606,000.00 |
| Dec 31, 2024 | 613,000.00 |
| Sep 30, 2024 | 493,000.00 |
| Jun 30, 2024 | 534,000.00 |
| Mar 31, 2024 | 144,000.00 |
| Dec 31, 2023 | 224,000.00 |
| Sep 30, 2023 | 229,000.00 |
| Jun 30, 2023 | 268,000.00 |
| Mar 31, 2023 | 300,000.00 |
| Dec 31, 2022 | 331,000.00 |